Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19 - 05/10/20
Doi : 10.1016/j.jaci.2020.07.018
Liqin Wang, PhD a 
, Dinah Foer, MD b, David W. Bates, MD, MSc a, Joshua A. Boyce, MD b, Li Zhou, MD, PhD a
, Dinah Foer, MD b, David W. Bates, MD, MSc a, Joshua A. Boyce, MD b, Li Zhou, MD, PhD a a Divisions of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass
b Allergy and Clinical Immunology, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
| L.W., D.W.B., and L.Z. are supported by the National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) (grant no. R01AI150295) and the Agency for Healthcare Research and Quality (grant no. R01HS025375). D.F. is supported by the NIH (grant no. T32AI007306). J.A.B. is supported by the NIH-NIAID (grant nos. R01AI078908, R01AI136041, R37AI052353, and U19AI095219) and the NIH-National Heart, Lung, and Blood Institute (grant no. R01HL117945). |
|
| This study was approved by the MGB Institutional Review Board (2020P000816). |
|
| Disclosure of potential conflict of interest: D. W. Bates consults for EarlySense, which makes patient safety monitoring systems; receives cash compensation from CDI (Negev), Ltd, which is a not-for-profit incubator for health IT startups; receives equity from ValeraHealth, which makes software to help patients with chronic diseases, Clew, which makes software to support clinical decision making in intensive care, MDClone, which takes clinical data and produces deidentified versions of it, and AESOP, which makes software to reduce medication error rates; and will be receiving research funding from IBM Watson Health. These financial interests have been reviewed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their institutional policies. J. A. Boyce reports consultant work for Sanofi and sits on the Scientific Advisory Board for Siolta Therapeutics and Sanofi-Aventis. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 146 - N° 4
P. 808-812 - octobre 2020 Retour au numéro
Article précédent
- IL-6–based mortality risk model for hospitalized patients with COVID-19
- Rocio Laguna-Goya, Alberto Utrero-Rico, Paloma Talayero, Maria Lasa-Lazaro, Angel Ramirez-Fernandez, Laura Naranjo, Alejandro Segura-Tudela, Oscar Cabrera-Marante, Edgar Rodriguez de Frias, Rocio Garcia-Garcia, Mario Fernández-Ruiz, Jose Maria Aguado, Joaquin Martinez-Lopez, Elena Ana Lopez, Mercedes Catalan, Antonio Serrano, Estela Paz-Artal
- Obesity may enhance the adverse effects of NO2 exposure in urban schools on asthma symptoms in children
- Perdita Permaul, Jonathan M. Gaffin, Carter R. Petty, Sachin N. Baxi, Peggy S. Lai, William J. Sheehan, Carlos A. Camargo, Diane R. Gold, Wanda Phipatanakul
Bienvenue sur EM-consulte, la référence des professionnels de santé.